4D Molecular Therapeutics Appoints Carolyne Zimmermann as Chief Business Officer
June 07, 2021 at 07:00 am EDT
4D Molecular Therapeutics announced the appointment of Carolyne Zimmermann as Chief Business Officer. Ms. Zimmermann brings nearly 20 years of leadership experience in life sciences corporate and business development from her prior roles at Johnson & Johnson Innovation and Novartis Pharmaceuticals. Ms. Zimmermann joins 4DMT from Johnson & Johnson Innovation where she served as Vice President, Transactions.